escitalopram/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on beck Depression Inventory (BDI) total score
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“There were no statistically significant differences between the groups: the mean difference for change in BDI-II severity was − 3.1 (95% confidence interval (CI) -8.66 to 2.53, p = 0.28) for nortriptyline vs. placebo and − 0.7 (95% CI -6.11 to 4.70, p = 0.80) for escitalopram vs. placebo (Supplementary Table 3).”
Quoted verbatim from Placebo-controlled three-armed pilot trial of Escitalopram or Nortriptyline for depressive symptoms in Parkinson's disease (ADepT-PD).. - Study
- RCT
- Duration
- 8 weeks
- Dose
- target 20 mg/day in patients aged 65 or under, 10 mg/day in patients over 65 or with hepatic impairment, titrated from 5 mg in two-weekly steps
- Population
- People with Parkinson's disease and depressive symptoms (BDI-II 14 or above) in a three-arm pilot trial of escitalopram, nortriptyline or placebo; change from baseline to 8 weeks, escitalopram versus placebo
Effect -0.7 mean difference, 95% CI -6.11 to 4.7
Placebo-controlled three-armed pilot trial of Escitalopram or Nortriptyline for depressive symptoms in Parkinson's disease (ADepT-PD).2026PMID:42101650Permalink
Keep reading
- Everything the graph holds on escitalopram
- Every compound studied against Beck Depression Inventory (BDI) total score
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45G0218J4W6SNGKBB9689J4